Results

Total Results: 330 records

Showing results for "sedation".

61. Living Systematic Review on Cannabis and Other Plant-Based Treatments for Chronic Pain: Surveillance Report 2 (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-250-cannabis-apps-a-e-surveillance-report-2-final.pdf
    February 01, 2022 - There may be a large increased risk of dizziness and sedation, and a moderate increased risk of nausea … high THC to CBD) may be associated with moderate improvement in pain severity and increased risk of sedation … no effect on overall function/disability (SOE: low; 2 RCTs) Harms: moderate increased risk of sedation … Combined THC/CBD may also be associated with a moderate to large increased risk of dizziness, sedation … Sedation for comparable THC to CBD ratio versus placebo (short-term, 4 weeks to 6 months followup)

62. Living Systematic Review on Cannabis and Other Plant-Based Treatments for Chronic Pain: Surveillance Report 2 (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-250-cannabis-apps-a-e-surveillance-report-2-final_0.pdf
    March 01, 2022 - There may be a large increased risk of dizziness and sedation, and a moderate increased risk of nausea … high THC to CBD) may be associated with moderate improvement in pain severity and increased risk of sedation … no effect on overall function/disability (SOE: low; 2 RCTs) Harms: moderate increased risk of sedation … Combined THC/CBD may also be associated with a moderate to large increased risk of dizziness, sedation … Sedation for comparable THC to CBD ratio versus placebo (short-term, 4 weeks to 6 months followup)

63. Living Systematic Review on Cannabis and Other Plant-Based Treatments for Chronic Pain: Surveillance Report 2 (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-250-cannabis-apps-a-e-surveillance-report-2-final_0_0.pdf
    March 01, 2022 - There may be a large increased risk of dizziness and sedation, and a moderate increased risk of nausea … high THC to CBD) may be associated with moderate improvement in pain severity and increased risk of sedation … no effect on overall function/disability (SOE: low; 2 RCTs) Harms: moderate increased risk of sedation … Combined THC/CBD may also be associated with a moderate to large increased risk of dizziness, sedation … Sedation for comparable THC to CBD ratio versus placebo (short-term, 4 weeks to 6 months followup)

64. Living Systematic Review on Cannabis and Other Plant-Based Treatments for Chronic Pain_Q1 Report (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/plant-based-chronic-pain-review-jan-2020.pdf
    January 01, 2020 - Specific adverse events of dizziness (mean, 32% vs. 9.5%), nausea (32% vs. 6%), and sedation (7% vs. … 10%).17 The 3-week trial and the 52-week cohort study also reported higher incidences of nausea and sedation … At 6 months, more patients in the gabapentin group reported sedation (60%) than in the other two groups … greater with THC/CBD (4 RCTs) Dizziness, nausea, sedation greater with THC (2 RCTs, 1 cohort study … ) Dizziness, sedation greater with THC vs. placebo (1 RCT) Abbreviations: AE = adverse event; CBD

65. Cer-250-Cannabis-Apps-A-E-Surveillance-Report-2 (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/product/pdf/cer-250-cannabis-apps-a-e-surveillance-report-2.pdf
    January 01, 2022 - There may be a large increased risk of dizziness and sedation, and a moderate increased risk of nausea … high THC to CBD) may be associated with moderate improvement in pain severity and increased risk of sedation … no effect on overall function/disability (SOE: low; 2 RCTs) Harms: moderate increased risk of sedation … Combined THC/CBD may also be associated with a moderate to large increased risk of dizziness, sedation … Sedation for comparable THC to CBD ratio versus placebo (short-term, 4 weeks to 6 months followup)

66. Living Systematic Review on Cannabis and Other Plant-Based Treatments for Chronic Pain: Surveillance Report 2 (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/product/pdf/cer-250-cannabis-apps-a-e-surveillance-report-2-final.pdf
    March 01, 2022 - There may be a large increased risk of dizziness and sedation, and a moderate increased risk of nausea … high THC to CBD) may be associated with moderate improvement in pain severity and increased risk of sedation … no effect on overall function/disability (SOE: low; 2 RCTs) Harms: moderate increased risk of sedation … Combined THC/CBD may also be associated with a moderate to large increased risk of dizziness, sedation … Sedation for comparable THC to CBD ratio versus placebo (short-term, 4 weeks to 6 months followup)

67. Restless-Legs Research-Protocol (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/pdf/restless-legs_research-protocol.pdf
    December 16, 2011 - Mirapex ® Yes Ritigotine Neupro ® Sedative- hypnotics Clonazepam Rivotril ® Tolerance; sedation … Gabapentin Neurontin ® Pregabalin Lyrica ® Opioids Hydrocodone -Vicodin ® -Lortab ® Sedation

68. Topic Suggestion Description | Effective Health Care Program
    effectivehealthcare.ahrq.gov/get-involved/nominated-topics/in-patients-with-dementia-what-is-the-effectiveness-of-psychological-treatment-ie-non-pharmacological-eg-cognitive-or-behavioral-therapy-for-individuals-with-dementia-environmental-and-behavioral-interventions-to-address-beha
    March 07, 2013 - Weight gain, sedation, mortality associated with off-label use of atypical antipsychotics in dementia

69. Living Systematic Review on Cannabis and Other Plant-Based Treatments for Chronic Pain: Quarterly Progress Report: February 2021 (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/pdf/plant-based-chronic-pain-review-q2.pdf
    May 01, 2021 - Specific adverse events of dizziness, nausea, and sedation were most frequently reported and occurred … greater with THC/CBD (4 RCTs) Dizziness, nausea, sedation greater with THC/CBD Abbreviations: … groups (2 RCTs) 0 WAEs, other outcomes not reported Specific Adverse Events Dizziness, nausea, sedation … greater with THC (2 RCTs, 1 cohort study) Dizziness, sedation greater with THC Abbreviations: … greater with THC vs. placebo (1 RCT) Sedation greater with THC vs.

70. Cannabis-Annual-Update2-Table-E5 (xls file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/cannabis-annual-update2-table-e5.xlsx
    March 13, 2023 - C Sedation 3 months: 31% (15/49) vs. 54% (28/52) vs. 33% (18/55), RR 0.57 (95% CI 0.35 to 0.93 for A … 1.29 (95% CI 0.75 to 2.21) Nausea: 16.7% (36/215) vs. 9.7% (21/216), RR 1.72 (95% CI 1.04 to 2.85) Sedation

71. Cannabis-2022-Update-Surv-Rep-1-App-F-5 (xls file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/cannabis-2022-update-surv-rep-1-app-F-5.xlsx
    January 01, 2022 - C Sedation 3 months: 31% (15/49) vs. 54% (28/52) vs. 33% (18/55), RR 0.57 (95% CI 0.35 to 0.93 for A … 1.29 (95% CI 0.75 to 2.21) Nausea: 16.7% (36/215) vs. 9.7% (21/216), RR 1.72 (95% CI 1.04 to 2.85) Sedation

72. Cannabis-2022-Surv-Rep-3-Table-F5 (xls file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/cannabis-2022-surv-rep-3-table-F5.xlsx
    January 01, 2022 - C Sedation 3 months: 31% (15/49) vs. 54% (28/52) vs. 33% (18/55), RR 0.57 (95% CI 0.35 to 0.93 for A … 1.29 (95% CI 0.75 to 2.21) Nausea: 16.7% (36/215) vs. 9.7% (21/216), RR 1.72 (95% CI 1.04 to 2.85) Sedation

73. Systematic Review on Nonopioid Pharmacologic Treatments for Chronic Pain: Surveillance Report (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/surveillance-report-1-nonopioid-treatments-chronic-pain.pdf
    December 01, 2021 - amitriptyline • SOE: Insufficient based on 1 RCT 1 new RCT (n=70) found no increase in SAE, nausea, or sedation … increase in cognitive AEs • SOE: Low based on 8 RCTs Large increase in dizziness, peripheral edema, sedation … oral THC/CBD associated in large increase in WAEs, dizziness, nausea, but no increase in SAEs or sedation

74. Comparative Effectiveness of Therapies for Children With Autism Spectrum Disorder | Effective Health Care (EHC) Program
    effectivehealthcare.ahrq.gov/products/autism-update/clinician
    September 23, 2014 - evidence insufficient] Harms Aripiprazole and risperidone are associated with significant weight gain, sedation

75. Autism-Update Clinician (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/pdf/autism-update_clinician.pdf
    September 01, 2014 - .  Harms � Aripiprazole and risperidone are associated with significant weight gain, sedation,

76. Living Systematic Review on Cannabis and Other Plant-Based Treatments for Chronic Pain - Quarterly Progress Report: May 2021 (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/pdf/plant-based-chronic-pain-review-q3.pdf
    September 01, 2021 - There may be a large increased risk of dizziness and sedation, and a moderate increased risk of nausea … high THC to CBD) may be associated with moderate improvement in pain severity and increased risk of sedation … Studies) SOE Dizziness Effect Size (N Studies) SOE Nausea Effect Size (N Studies) SOE Sedation … Combined THC/CBD may also be associated with a moderate to large increased risk of dizziness, sedation … Placebo Sedation 6 RCTs (N=866)1,2,4-7 Moderate Direct Consistent Imprecise Unknown Large effect

77. Disruptive-Behavior-Disorder Executive (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/disruptive-behavior-disorder_executive.pdf
    October 01, 2015 - this report, frequently occurring adverse events associated with risperidone included weight gain, sedation … Sedation was the most frequently reported harm in a study comparing aripiprazole (sedation occurring … in 50% of children) and ziprasidone (sedation occurring in 57% of children), while harms were generally … Adverse events associated with risperidone were generally mild across studies, with weight gain, sedation … Sedation was frequently reported with aripiprazole and ziprasidone.

78. Disposition of Comments CER 219 Antipsychotics for the Prevention and Treatment of Delirium (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/Disposition%20of%20Comments.pdf
    September 03, 2019 - review SPECIFICALLY involves antipsychotics for delirium, and NOT for other potential uses such as sedation … Public Reviewer #1 (Medicus, Jennifer [APA]) Results Page 29, sedation haloperidol v placebo – in … The absence of sedation with a given treatment is, in fact, important to know when assessing the potential … It is precisely because of the rare events in relation to sedation that we have been unable to come

79. Disposition of Comments CER 219 Antipsychotics for the Prevention and Treatment of Delirium (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/Disposition%20of%20Comments.pdf
    September 03, 2019 - review SPECIFICALLY involves antipsychotics for delirium, and NOT for other potential uses such as sedation … Public Reviewer #1 (Medicus, Jennifer [APA]) Results Page 29, sedation haloperidol v placebo – in … The absence of sedation with a given treatment is, in fact, important to know when assessing the potential … It is precisely because of the rare events in relation to sedation that we have been unable to come

80. Disposition of Comments CER 219 Antipsychotics for the Prevention and Treatment of Delirium (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/delirium-disposition-comments.pdf
    September 03, 2019 - review SPECIFICALLY involves antipsychotics for delirium, and NOT for other potential uses such as sedation … Public Reviewer #1 (Medicus, Jennifer [APA]) Results Page 29, sedation haloperidol v placebo – in … The absence of sedation with a given treatment is, in fact, important to know when assessing the potential … It is precisely because of the rare events in relation to sedation that we have been unable to come